|
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|
Mar 2021
|
The New England Journal of Medicine
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
|
Jan 2020
|
The New England Journal of Medicine
|
myelodysplastic syndromes (MDS)
|
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
|
Jun 2019
|
The Lancet Haematology
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency
|
Oct 2019
|
The Journal of Clinical Investigation
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms
|
Jul 2019
|
Surgical Pathology Clinic
|
myelodysplastic syndromes (MDS)
|
|
Impaired proliferative potential of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway
|
Mar 2014
|
Stem Cells Dev
|
myelodysplastic syndromes (MDS)
|
|
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia
|
Jan 2021
|
Seminars in Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
|
Sep 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity
|
Sep 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors
|
Sep 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
